Celldex Therapeutics Equity 2024

Celldex Therapeutics Aktienanalyse

What does Celldex Therapeutics do?

Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Celldex Therapeutics's Equity

Celldex Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Celldex Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Celldex Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Celldex Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Celldex Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Celldex Therapeutics stock

What is the equity of Celldex Therapeutics this year?

Celldex Therapeutics has equity of 429.17 M USD this year.

What was the equity of Celldex Therapeutics compared to the previous year?

The equity of Celldex Therapeutics has increased/decreased by 31.57% increased compared to the previous year.

What impact does a high equity have on investors of Celldex Therapeutics?

A high equity is advantageous for investors of Celldex Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Celldex Therapeutics?

A low equity can be a risk for investors of Celldex Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Celldex Therapeutics affect the company?

An increase in equity of Celldex Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Celldex Therapeutics affect the company?

A reduction in equity of Celldex Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Celldex Therapeutics?

Some factors that can affect the equity of Celldex Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Celldex Therapeutics so important for investors?

The equity of Celldex Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Celldex Therapeutics take to change the equity?

To change equity, Celldex Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Celldex Therapeutics pay?

Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Celldex Therapeutics?

The current dividend yield of Celldex Therapeutics is .

When does Celldex Therapeutics pay dividends?

Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celldex Therapeutics?

Celldex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Celldex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celldex Therapeutics located?

Celldex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celldex Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Celldex Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Celldex Therapeutics in the year 2023?

In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.

In which currency does Celldex Therapeutics pay out the dividend?

The dividends of Celldex Therapeutics are distributed in USD.